Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.

Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour EJ, Khoury JD.

Haematologica. 2019 Apr;104(4):749-755. doi: 10.3324/haematol.2018.205252. Epub 2018 Oct 25.

2.

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.

Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, Bai C, Rui L, Laleau R, Liu F, Ab O, Setiady Y, Yoder NC, Goldmacher VS, Chari RVJ, Pinkas J, Chittenden T.

Blood Adv. 2018 Apr 24;2(8):848-858. doi: 10.1182/bloodadvances.2018017517.

3.
4.

A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity.

Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, Wilhelm A, Modafferi HA, Singh R, Pinkas J, Goldmacher V, Lambert JM, Chari RV.

Mol Cancer Ther. 2016 Aug;15(8):1870-8. doi: 10.1158/1535-7163.MCT-16-0184. Epub 2016 May 23.

5.

Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing.

Widdison WC, Ponte JF, Coccia JA, Lanieri L, Setiady Y, Dong L, Skaletskaya A, Hong EE, Wu R, Qiu Q, Singh R, Salomon P, Fishkin N, Harris L, Maloney EK, Kovtun Y, Veale K, Wilhelm SD, Audette CA, Costoplus JA, Chari RV.

Bioconjug Chem. 2015 Nov 18;26(11):2261-78. doi: 10.1021/acs.bioconjchem.5b00430. Epub 2015 Sep 30.

PMID:
26355774
6.

Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies.

Widdison W, Wilhelm S, Veale K, Costoplus J, Jones G, Audette C, Leece B, Bartle L, Kovtun Y, Chari R.

Mol Pharm. 2015 Jun 1;12(6):1762-73. doi: 10.1021/mp5007757. Epub 2015 Apr 8.

PMID:
25826705
7.

High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.

Goldmacher VS, Audette CA, Guan Y, Sidhom EH, Shah JV, Whiteman KR, Kovtun YV.

PLoS One. 2015 Feb 11;10(2):e0117523. doi: 10.1371/journal.pone.0117523. eCollection 2015.

8.

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.

Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ.

MAbs. 2014 Mar-Apr;6(2):556-66. doi: 10.4161/mabs.27756. Epub 2014 Jan 8.

9.

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.

Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Gupta M, Pinkas J, Tibbitts J.

Mol Cancer Ther. 2012 May;11(5):1133-42. doi: 10.1158/1535-7163.MCT-11-0727. Epub 2012 Mar 9.

10.

Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.

Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, Goldmacher VS, Singh R, Kovtun Y, Widdison WC, Lambert JM, Chari RV.

J Med Chem. 2011 May 26;54(10):3606-23. doi: 10.1021/jm2002958. Epub 2011 May 4.

PMID:
21517041
11.

Can sediment total organic carbon and grain size be used to diagnose organic enrichment in estuaries?

Pelletier MC, Campbell DE, Ho KT, Burgess RM, Audette CT, Detenbeck NE.

Environ Toxicol Chem. 2011 Mar;30(3):538-47. doi: 10.1002/etc.414. Epub 2010 Dec 29.

PMID:
21298700
12.

Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.

Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H, Kovtun Y, Chari R, Jordan MA.

Mol Cancer Ther. 2010 Oct;9(10):2700-13. doi: 10.1158/1535-7163.MCT-10-0645.

13.

The sexual health of women after gynecologic malignancy.

Audette C, Waterman J.

J Midwifery Womens Health. 2010 Jul-Aug;55(4):357-62. doi: 10.1016/j.jmwh.2009.10.016. Review.

PMID:
20630362
14.

Antibody-maytansinoid conjugates designed to bypass multidrug resistance.

Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV.

Cancer Res. 2010 Mar 15;70(6):2528-37. doi: 10.1158/0008-5472.CAN-09-3546. Epub 2010 Mar 2.

15.

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.

Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R.

Bioconjug Chem. 2010 Jan;21(1):84-92. doi: 10.1021/bc900315y.

PMID:
19891424
16.

Comparison of 3 swab transport systems for direct release and recovery of aerobic and anaerobic bacteria.

Van Horn KG, Audette CD, Tucker KA, Sebeck D.

Diagn Microbiol Infect Dis. 2008 Dec;62(4):471-3. doi: 10.1016/j.diagmicrobio.2008.08.004. Epub 2008 Sep 23.

PMID:
18814991
17.

Comparison of the Copan ESwab system with two Amies agar swab transport systems for maintenance of microorganism viability.

Van Horn KG, Audette CD, Sebeck D, Tucker KA.

J Clin Microbiol. 2008 May;46(5):1655-8. doi: 10.1128/JCM.02047-07. Epub 2008 Mar 19.

18.

Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.

Prince HE, Lapé-Nixon M, Audette C, Van Horn K.

J Neuroimmunol. 2007 Oct;190(1-2):165-9. Epub 2007 Sep 21.

PMID:
17889376
19.

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blättler WA, Goldmacher VS.

Cancer Res. 2006 Mar 15;66(6):3214-21.

20.

Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.

Xie H, Audette C, Hoffee M, Lambert JM, Blättler WA.

J Pharmacol Exp Ther. 2004 Mar;308(3):1073-82. Epub 2003 Nov 21. Erratum in: J Pharmacol Exp Ther. 2004 Aug;310(2):844.

PMID:
14634038
21.

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.

Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK.

J Clin Oncol. 2003 Jan 15;21(2):211-22.

PMID:
12525512
22.

Classifying drug-related problems in home care.

Audette CM, Triller DM, Hamilton R, Briceland LL.

Am J Health Syst Pharm. 2002 Dec 15;59(24):2407-9. No abstract available.

PMID:
12503338
23.

Home care pharmacy: extending clinical pharmacy services beyond infusion therapy.

Triller DM, Hamilton RA, Briceland LL, Waite NM, Audette CM, Furman CA.

Am J Health Syst Pharm. 2000 Jul 15;57(14):1326-31.

PMID:
10918922
24.

Gabapentin vs amitriptyline for the treatment of peripheral neuropathy.

Fudin J, Audette CM.

Arch Intern Med. 2000 Apr 10;160(7):1040-1. No abstract available.

PMID:
10761972
25.

Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities.

Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, Mechoulam R.

J Med Chem. 1992 Aug 21;35(17):3135-41.

PMID:
1507202
26.

G-protein mediation of cannabinoid-induced phospholipase activation.

Audette CA, Burstein SH, Doyle SA, Hunter SA.

Pharmacol Biochem Behav. 1991 Nov;40(3):559-63.

PMID:
1666919
27.

Elevation of brain prostaglandin E2 levels in rodents by delta 1-tetrahydrocannabinol.

Hunter SA, Audette CA, Burstein S.

Prostaglandins Leukot Essent Fatty Acids. 1991 Jul;43(3):185-90.

PMID:
1651514
28.

Detection of cannabinoid receptors by photoaffinity labelling.

Burstein SH, Audette CA, Charalambous A, Doyle SA, Guo Y, Hunter SA, Makriyannis A.

Biochem Biophys Res Commun. 1991 Apr 15;176(1):492-7.

PMID:
1850270
29.
30.

Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid.

Burstein SH, Audette CA, Doyle SA, Hull K, Hunter SA, Latham V.

J Pharmacol Exp Ther. 1989 Nov;251(2):531-5.

PMID:
2553925

Supplemental Content

Loading ...
Support Center